寻常型天疱疮的治疗难点与对策

doi:10.35541/cjd.20240233

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (10): 891-894.doi: 10.35541/cjd.20240233

寻常型天疱疮的治疗难点与对策

潘萌,王麒钧

上海交通大学医学院附属瑞金医院皮肤科，上海 200025

收稿日期:2024-04-30 修回日期:2024-08-12 发布日期:2024-09-29
通讯作者: 潘萌 E-mail:pm10633@rjh.com.cn
基金资助:
国家自然科学基金（82173407）；上海高水平地方高校创新团队（二期）协同团队（SHSMU-ZDCX20211002）

Challenges and strategies for the treatment of pemphigus vulgaris

Pan Meng, Wang Qijun

Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2024-04-30 Revised:2024-08-12 Published:2024-09-29
Contact: Pan Meng E-mail:pm10633@rjh.com.cn
Supported by:
National Natural Science Foundation of China （82173407）; Innovative Research Team of High-level Local Universities in Shanghai （SHSMU-ZDCX20211002）

摘要/Abstract

摘要： 【摘要】寻常型天疱疮是重症难治性自身免疫性皮肤病，病程迁延反复，需要专科医生的长期管理。由于该病罕见，临床医生对治疗方案的认知相对不足，存在一定误区。本文重点归纳了近年来寻常型天疱疮治疗中的难点及相应对策，以期提高临床医师对寻常型天疱疮的认识，改善患者的预后。

关键词: 天疱疮, 糖皮质激素, 利妥昔单抗, 免疫抑制剂, 免疫球蛋白类, 静脉内, 治疗

Abstract: 【Abstract】 Pemphigus vulgaris is a severe and refractory autoimmune skin disease with a prolonged and recurrent course, requiring long-term management by specialized clinicians. Due to the rarity of the disease, clinicians often have a relatively insufficient understanding of its treatment regimens, resulting in some misunderstandings. This article focuses on the challenges in the treatment of pemphigus vulgaris in recent years, as well as the corresponding strategies, in order to enhance clinical physicians′ understanding of pemphigus vulgaris and improve patient prognosis.

Key words: Pemphigus, Glucocorticoids, Rituximab, Immunosuppressive agents, Immunoglobulins, intravenous, Therapy

潘萌王麒钧. 寻常型天疱疮的治疗难点与对策[J]. 中华皮肤科杂志, 2024,57(10):891-894. doi:10.35541/cjd.20240233

Pan Meng, Wang Qijun. Challenges and strategies for the treatment of pemphigus vulgaris[J]. Chinese Journal of Dermatology, 2024, 57(10): 891-894.doi:10.35541/cjd.20240233

参考文献 35

［1］	Montagnon CM, Tolkachjov SN, Murrell DF, et al. Intraepithelial autoimmune blistering dermatoses: clinical features and diagnosis［J］. J Am Acad Dermatol, 2021,84（6）:1507⁃1519. doi: 10.1016/j.jaad.2020.11.075.
［2］	Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:1900⁃1913. doi: 10.1111/jdv.16752.
［3］	Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts［J］. J Am Acad Dermatol, 2020,82（3）:575⁃585.e1. doi: 10. 1016/j.jaad.2018.02.021.
［4］	Zhao W, Wang J, Zhu H, et al. Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies［J］. Clin Rev Allergy Immunol, 2021,61（3）:351⁃362. doi: 10.1007/s12016⁃021⁃08882⁃1.
［5］	Chu CY, Lee CH, Lee HE, et al. Taiwanese dermatological association （TDA） consensus for the management of pemphigus［J］. J Formos Med Assoc, 2023,122（7）:540⁃548. doi: 10.1016/j.jfma.2022.12.005.
［6］	中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议（2020）［J］. 中华皮肤科杂志, 2020,53（1）:1⁃7. doi: 10.35541/cjd.20190703.
［7］	Joly P, Maho⁃Vaillant M, Prost⁃Squarcioni C, et al. First⁃line rituximab combined with short⁃term prednisone versus prednisone alone for the treatment of pemphigus （Ritux 3）: a prospective, multicentre, parallel⁃group, open⁃label randomised trial［J］. Lancet, 2017,389（10083）:2031⁃2040. doi: 10.1016/S0140⁃6736（17）30070⁃3.
［8］	Mazaherpour E, Kianfar N, Dasdar S, et al. Applicability of glucocorticoid toxicity index in pemphigus: comparison between two groups of rituximab⁃treated and rituximab⁃naïve patients［J］. Dermatol Ther, 2022,35（12）:e15902. doi: 10.1111/dth.15902.
［9］	Leshem YA, Atzmony L, Dudkiewicz I, et al. Venous thromboembolism in patients with pemphigus: a cohort study［J］. J Am Acad Dermatol, 2017,77（2）:256⁃260. doi: 10.1016/j.jaad. 2017.01.059.
［10］	Bonnesen K, Poulsen C, Schmidt S, et al. Autoimmune blistering disorders and cardiovascular risks: a population⁃based cohort study［J］. J Am Acad Dermatol, 2024,91（1）:82⁃90. doi: 10. 1016/j.jaad.2024.02.052.
［11］	Saha M, Powell AM, Bhogal B, et al. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus［J］. Br J Dermatol, 2010,162（4）:790⁃797. doi: 10. 1111/j.1365⁃2133.2009.09590.x.
［12］	Abraham A, Roga G, Job AM. Pulse therapy in pemphigus: ready reckoner［J］. Indian J Dermatol, 2016,61（3）:314⁃317. doi: 10.4103/0019⁃5154.182428.
［13］	潘萌, 王晶莹. 中国天疱疮的诊治现状及思考［J］. 诊断学理论与实践, 2023,22（3）:209⁃214. doi: 10.16150/j.1671⁃2870. 2023.03.01.
［14］	张弦, 许人超, 元慧杰, 等. 寻常型天疱疮63例疗效分析［J］. 江苏医药, 2016,42（1）:97⁃99.
［15］	张雪彤, 潘萌. 硫唑嘌呤的药物基因型及其在天疱疮治疗中的作用［J］. 中国皮肤性病学杂志, 2020,34（5）:596⁃600. doi: 10.13735/j.cjdv.1001⁃7089.201905004.
［16］	Martin LK, Werth VP, Villaneuva EV, et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus［J］. J Am Acad Dermatol, 2011,64（5）:903⁃908. doi: 10.1016/j.jaad.2010.04.039.
［17］	Zhang H, Wang Y, Li S, et al. Prevalence and clinical features of herpes simplex virus infection in oral lesions of pemphigus vulgaris: a prospective, cross⁃sectional study［J］. J Am Acad Dermatol, 2022,87（5）:1201⁃1203. doi: 10.1016/j.jaad.2022.03. 015.
［18］	Wiedenmayer N, Vollmer AS, Winkler JK, et al. Successful treatment of severe pemphigus vulgaris with reduced side effects using a novel IVIg preparation［J］. Dermatol Ther （Heidelb）, 2024,14（7）:1969⁃1974. doi: 10.1007/s13555⁃024⁃01191⁃3.
［19］	郑捷. 个体化:天疱疮的治疗原则——以尽可能少的皮质类固醇治疗天疱疮［J］. 临床皮肤科杂志, 2000,29（6）:382⁃383. doi: 10.3969/j.issn.1000⁃4963.2000.06.041.
［20］	Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus［J］. J Am Acad Dermatol, 2008,58（6）:1043⁃1046. doi: 10.1016/j.jaad.2008.01.012.
［21］	Genovese G, Maronese CA, Casazza G, et al. Clinical and serological predictors of relapse in pemphigus: a study of 143 patients［J］. Clin Exp Dermatol, 2022,47（1）:98⁃106. doi: 10. 1111/ced.14854.
［22］	Wang M, Li J, Shang P, et al. Evaluation of clinical factors and outcome of systemic glucocorticoid therapy discontinuation in patients with pemphigus achieving complete remission［J］. J Dermatol, 2023,50（10）:1347⁃1352. doi: 10.1111/1346⁃8138. 16838.
［23］	朱海琴, 潘萌, 李金枝, 等. 联合rituximab治疗一例寻常型天疱疮的疗效观察［J］. 中华皮肤科杂志, 2009,42（8）:566⁃568. doi: 10.3760/cma.j.issn.0412⁃4030.2009.08.015.
［24］	Werth VP, Joly P, Mimouni D, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris［J］. N Engl J Med, 2021,384（24）:2295⁃2305. doi: 10.1056/NEJMoa 2028564.
［25］	Tedbirt B, Maho⁃Vaillant M, Houivet E, et al. Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first⁃line therapy: follow⁃up of the ritux 3 trial［J］. JAMA Dermatol, 2024,160（3）:290⁃296. doi: 10.1001/jamadermatol.2023.5679.
［26］	Hsu HC, Huang PW, Cho YT, et al. Cotrimoxazole as a preventative intervention for pneumocystis pneumonia in pemphigus patients treated with rituximab: a retrospective study［J］. Dermatol Ther （Heidelb）, 2023,13（7）:1561⁃1576. doi: 10. 1007/s13555⁃023⁃00953⁃9.
［27］	Faraji H, Daneshpazhooh M, Ehsani AH, et al. Evaluating the risk⁃to⁃benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: a retrospective study with 494 patients［J］. Dermatol Ther, 2022,35（2）:e15257. doi: 10.1111/dth.15257.
［28］	Zhou X, Zhan T, Xu X, et al. The efficacy and safety of low⁃dose rituximab in the treatment of pemphigus vulgaris: a cohort study［J］. J Dermatolog Treat, 2024,35（1）:2302071. doi: 10.1080/09546634.2024.2302071.
［29］	Mao J, Bao S, Chen Y, et al. Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: a multi⁃centre cohort study［J］. J Eur Acad Dermatol Venereol, 2024. doi: 10.1111/jdv.20245.
［30］	Murrell DF, Caux F, Patsatsi A, et al. Efficacy and safety of rilzabrutinib in pemphigus: PEGASUS phase 3 randomized study［J］. J Invest Dermatol, 2024,144（8）:1762⁃1771.e6. doi: 10. 1016/j.jid.2024.02.023.
［31］	Ruan J, Zhang X, Zheng M. Belimumab for the treatment of pemphigus［J］. Dermatol Ther, 2022,35（8）:e15621. doi: 10. 1111/dth.15621.
［32］	Goebeler M, Bata⁃Csörgő Z, De Simone C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phaseⅡ multicentre, open⁃label feasibility trial［J］. Br J Dermatol, 2022,186（3）:429⁃439. doi: 10.1111/bjd.20782.
［33］	Chen J, Chen S, Wu X, et al. The complicated use of dupilumab in the treatment of atypical generalized pemphigus erythematous: a report of two cases［J］. Hum Vaccin Immunother, 2023,19（1）:2151290. doi: 10.1080/21645515.2022.2151290.
［34］	骆彦霏, 王远志, 符文好, 等. 巴瑞替尼联合糖皮质激素治疗天疱疮的疗效及安全性评价［J］. 中国皮肤性病学杂志, 2024,38（4）:409⁃413. doi: 10.13735/j.cjdv.1001⁃7089.202303123.
［35］	Delvaux C, Bohelay G, Sitbon IY, et al. Activity of apremilast in a patient with severe pemphigus vulgaris: case report［J］. Front Immunol, 2024,15:1404185. doi: 10.3389/fimmu.2024.1404185.

[1]	王瑞霞曲岩磊艾文锦闫琳曲才杰史同新. 非大疱性嗜中性红斑狼疮1例[J]. 中华皮肤科杂志, 2024, 57(9): 832-834.
[2]	向茜张凌燕钟琳高奕邱逦. 鲜红斑痣多模态超声表现及在光动力疗效评估中的应用研究[J]. 中华皮肤科杂志, 2024, 57(9): 801-806.
[3]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.
[4]	任伟琦邹雅茹潘敏. 大疱性类天疱疮患者继发感染危险因素的研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 770-772.
[5]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 57(8): 743-746.
[6]	屈园园王鹏张景展李婷婷康晓静. circRNA_0001400/RELL1调控激活丝裂原激活蛋白激酶信号通路在卡波西肉瘤发生发展中的作用研究[J]. 中华皮肤科杂志, 2024, 57(8): 685-692.
[7]	夏曼琪邵蕾黄琼霄田歆梁毅敏黄婷梁景耀刘玉梅. 度普利尤单抗治疗结节性痒疹疗效与安全性的多中心回顾性分析[J]. 中华皮肤科杂志, 2024, 57(8): 679-684.
[8]	罗莉张博娜吴畏汤文静李岳华刘晓莉马雅楠李翠翠齐梦岩孙妮石琼. [开放获取] 308 nm准分子激光与308 nm准分子光治疗194例儿童白癜风的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2024, 57(8): 721-727.
[9]	陈浩天刘莲张婷刘青锋李晓雪刁萍蒋献. 鲜红斑痣发病及进展机制研究进展[J]. 中华皮肤科杂志, 2024, 57(7): 661-664.
[10]	杨开颖田博闻蓝超婷. 基于非靶向代谢组学分析婴幼儿血管瘤内皮细胞代谢特征[J]. 中华皮肤科杂志, 2024, 57(7): 601-609.
[11]	刁萍韩成龙刘莲周慧李二龙蒋献. 海姆泊芬光动力治疗成人鲜红斑痣的疗效及其影响因素分析：一项回顾性研究[J]. 中华皮肤科杂志, 2024, 57(7): 595-600.
[12]	张婷刘莲陈浩天魏丹凤刘绪刁萍刘青锋蒋献. 595 nm脉冲染料激光治疗155例婴幼儿鲜红斑痣疗效回顾性分析[J]. 中华皮肤科杂志, 2024, 57(7): 610-615.
[13]	海姆泊芬光动力疗法治疗鲜红斑痣共识制订专家组. [开放获取] 海姆泊芬光动力疗法治疗鲜红斑痣专家共识（2024）[J]. 中华皮肤科杂志, 2024, 57(7): 581-589.
[14]	隋长霖常晓赵琪朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 570-574.
[15]	王林霞张立明史美慧高兴华陈洪铎肖汀. 慢性自发性荨麻疹伴与不伴血管性水肿患者131例临床特征回顾分析[J]. 中华皮肤科杂志, 2024, 57(6): 510-515.

寻常型天疱疮的治疗难点与对策

Challenges and strategies for the treatment of pemphigus vulgaris

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 35

相关文章 15

Metrics

本文评价

推荐阅读 10